Emily Luisa Hill Sells 11,448 Shares of Replimune Group (NASDAQ:REPL) Stock

Replimune Group, Inc. (NASDAQ:REPL) CFO Emily Luisa Hill sold 11,448 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $12.97, for a total value of $148,480.56. Following the completion of the sale, the chief financial officer owned 225,108 shares in the company, valued at approximately $2,919,650.76. This represents a 4.84% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Replimune Group Stock Performance

NASDAQ REPL opened at $15.19 on Friday. The business has a 50 day moving average price of $10.55 and a 200 day moving average price of $7.74. The company has a market capitalization of $1.28 billion, a P/E ratio of -4.49 and a beta of 0.88. Replimune Group, Inc. has a 1-year low of $1.50 and a 1-year high of $15.71. The company has a debt-to-equity ratio of 0.63, a current ratio of 4.79 and a quick ratio of 4.79.

Replimune Group (NASDAQ:REPL) last posted its earnings results on Monday, June 29th. The company reported ($0.76) EPS for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.10). Sell-side analysts expect that Replimune Group, Inc. will post -2.7 EPS for the current fiscal year.

Key Headlines Impacting Replimune Group

Here are the key news stories impacting Replimune Group this week:

• Positive Sentiment: $150 million financing improves liquidity: Replimune priced a $150 million underwritten offering, providing additional capital to fund development of RP1 and its broader oncology pipeline. The financing reduces near-term funding concerns, although it will dilute existing shareholders. Replimune Announces Pricing of $150 Million Underwritten Offering
• Positive Sentiment: Analysts became more bullish: JPMorgan raised its price target to $20, while other firms upgraded or increased their targets, helping support investor sentiment. The broader analyst consensus remains below the recent trading range, however. Replimune Shares Rise After Pricing of Offering
• Neutral Sentiment: Insiders sold shares for tax withholding: The CEO, CFO, chief accounting officer and another insider collectively sold about 69,868 shares worth approximately $906,000. The filings said the transactions were used to cover taxes on vested equity awards, and the executives retained substantial holdings, limiting the negative signal. SEC insider transaction filing
• Negative Sentiment: Multiple law firms publicized a securities class action: The lawsuit alleges that Replimune misled investors about RP1’s efficacy, commercial readiness and unresolved FDA concerns. The allegations relate to securities purchased from October 20, 2025, through April 10, 2026, when shares fell after the FDA rejected the company’s application and said previously communicated study-design concerns had not been addressed. The lead-plaintiff deadline is October 5, 2026. The claims have not been proven, but the litigation creates legal, financial and reputational uncertainty. Replimune securities lawsuit notice

Institutional Trading of Replimune Group

Large investors have recently made changes to their positions in the stock. International Assets Investment Management LLC purchased a new position in Replimune Group in the 4th quarter valued at about $29,000. Russell Investments Group Ltd. increased its stake in Replimune Group by 3,638.9% during the third quarter. Russell Investments Group Ltd. now owns 7,777 shares of the company’s stock worth $33,000 after acquiring an additional 7,569 shares during the last quarter. CWM LLC raised its holdings in shares of Replimune Group by 248.6% in the 4th quarter. CWM LLC now owns 4,047 shares of the company’s stock worth $39,000 after purchasing an additional 2,886 shares during the period. Essential Partners LLC lifted its stake in shares of Replimune Group by 562,400.0% in the 1st quarter. Essential Partners LLC now owns 5,625 shares of the company’s stock valued at $43,000 after purchasing an additional 5,624 shares in the last quarter. Finally, BNP Paribas Financial Markets grew its holdings in shares of Replimune Group by 99.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 13,762 shares of the company’s stock worth $58,000 after purchasing an additional 6,873 shares during the period. Institutional investors and hedge funds own 92.53% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on REPL. Wall Street Zen raised shares of Replimune Group from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 23rd. Cantor Fitzgerald restated an “overweight” rating on shares of Replimune Group in a research report on Wednesday. Wolfe Research raised shares of Replimune Group to an “outperform” rating in a report on Tuesday, August 4th. JPMorgan Chase & Co. increased their price target on shares of Replimune Group from $17.00 to $20.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. Finally, Piper Sandler raised shares of Replimune Group from a “hold” rating to a “strong-buy” rating in a research note on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $11.86.

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.